StreetAlpha.app
Home › Stocks › VTRS

Viatris Inc (VTRS)

Healthcare
$20.45
▼ −1.40%
LAST CLOSE · NOV 17

Viatris makes and sells generic, branded and newer medicines for patients around the world. It last closed at $20.45 on Nov 17, down 1.40% on the day. The average 12-month price target from 7 analysts is $22.14 (+8.3% from the last close), with a high of $26.00 and a low of $14.00. Analyst consensus is Buy, based on the latest ratings from 7 firms (4 buy, 3 hold, 0 sell). In the past 30 days there were 8 dark pool prints totaling $16.6M, the largest $5.1M.

AI Auto Pilots
Is VTRS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$14.7B
+4.3% vs a year ago
EPS (diluted)
−$0.53
Free cash flow
$2.1B
14.3% margin
Gross margin
35.3%
$5.2B gross profit
Valuation
Market cap
$23.4B
1.15B shares
P/E
–
No P/E while losing money
Price to sales
1.6
Market cap over revenue
Dividend yield
2.35%
$0.48 a share over 12 months
Balance sheet
Cash & equivalents
$1.8B
At Sep 30
Debt
$13.3B
At Sep 30
Buybacks
$385.1M
Last 12 months
CEOScott A. Smith
Employees30,000 (Dec 31, 2025)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $17.9B$17.9BFY2021FY2022: $16.3B$16.3BFY2022FY2023: $15.4B$15.4BFY2023FY2024: $14.7B$14.7BFY2024FY2025: $14.3B$14.3BFY2025

From VTRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
7firms
4 Buy3 Hold0 Sell
Each firm's latest rating on VTRS in the past 90 days
Average 12-month target
$22.14
▲ 8.3% upside

Based on 7 analysts who set a price target on VTRS in the past 90 days. The average target is $22.14, with a high of $26.00 and a low of $14.00, compared with the last close of $20.45.

Low $14.00Avg $22.14High $26.00
Blue marker: last close $20.45
Highest target$26.00
Average target$22.14
Lowest target$14.00
Latest rating changes
Leerink PartnersTarget raised
Nov 17Buy$20 → $24
BarclaysTarget raised
Nov 16Buy$22 → $25
JP MorganTarget raised
Nov 7Hold$20 → $21
Piper SandlerTarget raised
Oct 26Hold$13 → $14
JP MorganMaintained
Oct 21Hold$20
DateFirmActionRatingPrice target
Nov 17Leerink PartnersTarget raisedBuy$20 → $24
Nov 16BarclaysTarget raisedBuy$22 → $25
Nov 7JP MorganTarget raisedHold$20 → $21
Oct 26Piper SandlerTarget raisedHold$13 → $14
Oct 21JP MorganMaintainedHold$20
Loading…

Technical Analysis

VTRS · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 5% above its 20 day and 11% above its 50 day average. It is 20% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot S1 at $20.34, and the nearest resistance the Pivot at $20.51.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 2.6%/day
Key levels
$21.2052 week high+3.7%
$21.20Swing high (Nov 12)+3.7%
$20.62Pivot R1+0.8%
$20.51Pivot+0.3%
$20.45Last close
$20.34Pivot S1−0.5%
$19.4920 day average−4.7%
$18.64Swing low (Nov 3)−8.9%
$18.2650 day average−10.7%
$17.52100 day average−14.3%
$16.31200 day average−20.2%
$10.1552 week low−50.4%
Indicators
RSI (14)64.04Strong, overbought above 70Neutral
MACD0.76Above its signal lineBullish
Stochastic80.5Near the top of its rangeOverbought
ADX (14)36.9Trending up
Williams %R-29.3Oversold below −80, overbought above −20Neutral
CCI (20)81.8Oversold below −100, overbought above 100Neutral
Rate of change+8.1%Change over 10 sessionsBullish
ATR (14)$0.53Typical daily range, 2.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for VTRS

What happened before

See how VTRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VTRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VTRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VTRS in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
8
Notional
$16.6M
Largest print
$5.1M
Loading…

VTRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●471 buying vs 411 selling
  • ▼Held by funds -2.7 pts
  • ●Funds holding -1
  • ▲Superinvestors: 5 added, 1 cut
  • ▲Put/call 0.30 to 0.18
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,0341,035−0.1%
In funds' top 101516−6.3%
Held by funds89.3%92.0%−2.7 pts
New / increased98 / 37397 / 369+1.1%
Reduced / sold out321 / 90324 / 98−2.6%
Put/call ratio0.180.30−38.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VTRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VTRS Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$385.1M
1.6% yield
Left in program
$699.5M
3.0% of value
Shares outstanding, 12 months
−0.5%
Fewer shares
Last quarter
$150.0M
Sep 2026
Avg price paid, last quarter
$16.83
8.9M shares bought
S&P 500 rank by spending
#295 of 358
 
Spent each quarter, last 3 yearsTop bar $249.6M
Dec 2023: $0Mar 2024: $249.6M, average price $12.97Jun 2024: $0Sep 2024: $0Dec 2024: $0Mar 2025: $175.5M, average price $9.43Jun 2025: $175.0M, average price $8.65Sep 2025: $68.0M, average price $10.01Dec 2025: $82.1M, average price $10.20Mar 2026: $0Jun 2026: $150.0M, average price $16.01Sep 2026: $150.0M, average price $16.83
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 5, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VTRS is in one of them and how their past VTRS trades turned out.

VTRS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VTRS in an article yet. Here's the latest on the wider market.

VTRS Congress Trades

All congress trades →
Trades, 12 months
3
Buys
2
67%
Sells
1
33%
People
2
Last filed Jun 9
Who traded VTRS · since 2020
Latest 5 filings of 42
$1K – $15KTraded May 27, 2026Filed Jun 9, 2026
$15K – $50KTraded Jan 29, 2026Filed Feb 6, 2026
$1K – $15KTraded Nov 18, 2025Filed Dec 15, 2025
$1K – $15KTraded Apr 8, 2025Filed May 8, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Mar 31, 2025Filed Apr 7, 2025
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell$1K – $15KMay 27, 2026Jun 9, 202613 d
Ro KhannaD · CABuy$15K – $50KJan 29, 2026Feb 6, 20268 d
Gilbert CisnerosD · CABuy$1K – $15KNov 18, 2025Dec 15, 202527 d
Rob BresnahanR · PASell$1K – $15KApr 8, 2025May 8, 202530 d
Gilbert CisnerosD · CASell (partial)$1K – $15KMar 31, 2025Apr 7, 20257 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Viatris

Viatris is a healthcare company based in Canonsburg, Pennsylvania, that makes and sells medicines for patients around the world. Its portfolio includes generic medicines, including complex products, familiar branded medicines, and newer medicines it is developing. It runs manufacturing, packaging and distribution sites worldwide and serves patients and other customers in many countries.

Headquarters
Canonsburg, PA
Founded
2020